Skip to main content
ZYME
NASDAQ Life Sciences

Zymeworks Secures $250M Non-Dilutive Royalty Financing, Reports Q4 & FY25 Results

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$23.4
Mkt Cap
$1.756B
52W Low
$9.03
52W High
$28.49
52W Position info
159% above low
Off High info
18% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ZYME has more than doubled off its 52-week low of $9.03.

Summary

Zymeworks reported its fourth quarter and full year 2025 financial results and provided a comprehensive corporate update. The most significant development is the company's new $250.0 million non-recourse royalty-backed note financing arrangement with Royalty Pharma. This non-dilutive capital is earmarked to support Zymeworks' stock repurchase program and potential strategic acquisitions, aligning with its refreshed leadership and focused strategy for long-term value creation. The company also outlined its R&D priorities for 2026 and beyond, including ongoing Phase 1 studies and planned IND submissions for new multispecific programs. This substantial capital infusion provides Zymeworks with significant financial flexibility to execute its strategic initiatives without shareholder dilution, representing a material positive development. Investors will be watching for the execution of the share repurchase program, progress on the R&D pipeline, and any future strategic acquisitions.

At the time of this announcement, ZYME was trading at $23.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $9.03 to $28.49. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ZYME - Latest Insights

ZYME
Nov 09, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.81
Real-time Price: $25.84 info
Change: -$4.97 (-16%) info
Market Cap: $1.826B info
ZYME
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.81
Real-time Price: $25.84 info
Change: -$4.97 (-16%) info
Market Cap: $1.826B info
ZYME
Nov 09, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $30.81
Real-time Price: $25.84 info
Change: -$4.97 (-16%) info
Market Cap: $1.826B info
ZYME
Oct 24, 2026, 2:30 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $28.55
Real-time Price: $25.84 info
Change: -$2.71 (-10%) info
Market Cap: $1.826B info
ZYME
Oct 23, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $28.99
Real-time Price: $25.84 info
Change: -$3.15 (-11%) info
Market Cap: $1.826B info